Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KR230109 Phase 2 trial in mild to moderate acne vulgaris
ChiCTR2500115228Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KR230109 in acne vulgaris (3 arms), sponsored by Peking University People's Hospital. Primary endpoints: Percentage change in non-inflammatory facial lesion count at Week 12 versus baseline compared to placebo and Percentage change in inflammatory facial lesion count at Week 12 versus baseline compared to placebo. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
KR230109
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ChiCTR2500115228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115228.